Antibody engineering technology company Creative Biolabs has formed a strategic expansion of its next-generation bioconjugate (xDC) development services.
Collaboration will apply Aignostics' AI-technology to PanCAN's multimodal pancreatic cancer dataset
The tool helps to distinguish between types of dementia that require different treatments
The service supports biopharmaceutical manufacturers
The spectrometer is designed to accelerate iomarket discovery and validation while supporting biomedical research and epidemiology studies
Sign in to your account